
Happiness Biotech Group Limited HAPP
Happiness Biotech Group Limited Anteile | HAPP
Anteile Jährlich Happiness Biotech Group Limited
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 4.73 M | 5.68 M | 40.5 M | 26.2 M | 23.8 M | 23 M | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 40.5 M | 4.73 M | 20.7 M |
Anteile Vierteljährlich Happiness Biotech Group Limited
| 2026-Q2 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 23 M | - | - | 4.73 M | - | 4.73 M | 5.68 M | - | - | - | - | - | - | - | 30.5 M | - | 25.9 M | - | 25 M | - | - | - | 23 M | - | - | - | 23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 30.5 M | 4.73 M | 18.4 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Sierra Oncology
SRRA
|
13.3 M | - | -0.05 % | $ 1.34 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
8.51 M | $ 5.31 | 2.42 % | $ 45.2 M | ||
|
Atea Pharmaceuticals
AVIR
|
81.5 M | $ 4.16 | 2.97 % | $ 339 M | ||
|
Tenax Therapeutics
TENX
|
39.2 M | $ 1.65 | -4.07 % | $ 64.7 M | ||
|
Vaccinex
VCNX
|
2.1 M | - | -61.37 % | $ 654 K | ||
|
Trevi Therapeutics
TRVI
|
135 M | $ 12.51 | -0.83 % | $ 1.69 B | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
93.7 M | - | -19.68 % | $ 18.4 M | ||
|
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | ||
|
Taysha Gene Therapies
TSHA
|
320 M | $ 4.0 | 0.88 % | $ 1.28 B | ||
|
Jounce Therapeutics
JNCE
|
51.7 M | - | - | $ 98.4 M | ||
|
Verona Pharma plc
VRNA
|
652 M | - | - | $ 69.7 B | ||
|
Corner Growth Acquisition Corp.
COOL
|
9.83 M | - | -0.89 % | $ 114 M | ||
|
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | ||
|
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 49.0 | -0.79 % | $ 4.41 B | ||
|
Corvus Pharmaceuticals
CRVS
|
79 M | $ 10.44 | -0.9 % | $ 824 M | ||
|
UroGen Pharma Ltd.
URGN
|
48.1 M | $ 34.05 | -1.29 % | $ 1.64 B | ||
|
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | ||
|
United Therapeutics Corporation
UTHR
|
44.3 M | $ 593.02 | 0.94 % | $ 26.3 B | ||
|
Vericel Corporation
VCEL
|
50.3 M | $ 42.99 | 1.08 % | $ 2.16 B | ||
|
Veracyte
VCYT
|
78.6 M | $ 48.22 | 0.61 % | $ 3.79 B | ||
|
Champions Oncology
CSBR
|
13.8 M | $ 4.82 | 2.12 % | $ 66.7 M | ||
|
Mersana Therapeutics
MRSN
|
123 M | - | - | $ 3.56 B | ||
|
Vir Biotechnology
VIR
|
139 M | $ 11.02 | 4.27 % | $ 1.53 B | ||
|
Viking Therapeutics
VKTX
|
113 M | $ 24.23 | -0.72 % | $ 2.73 B | ||
|
CymaBay Therapeutics
CBAY
|
106 M | - | - | $ 3.45 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
59.3 M | - | - | $ 384 M | ||
|
Cabaletta Bio
CABA
|
100 M | $ 1.34 | -9.18 % | $ 135 M | ||
|
CytomX Therapeutics
CTMX
|
138 M | $ 2.23 | -4.09 % | $ 308 M | ||
|
Vanda Pharmaceuticals
VNDA
|
58.9 M | $ 3.95 | -1.62 % | $ 233 M | ||
|
Allakos
ALLK
|
88.8 M | - | - | $ 28.6 M | ||
|
Timber Pharmaceuticals
TMBR
|
2.11 M | - | - | $ 717 K | ||
|
Verrica Pharmaceuticals
VRCA
|
10.7 M | $ 3.4 | -3.68 % | $ 36.2 M | ||
|
Viridian Therapeutics
VRDN
|
102 M | $ 23.31 | 4.2 % | $ 2.37 B | ||
|
G1 Therapeutics
GTHX
|
51.7 M | - | - | $ 370 M | ||
|
Verastem
VSTM
|
69.3 M | $ 9.9 | -1.34 % | $ 686 M | ||
|
VistaGen Therapeutics
VTGN
|
38.1 M | $ 0.17 | -3.9 % | $ 6.47 M | ||
|
Voyager Therapeutics
VYGR
|
58.7 M | $ 1.76 | 0.86 % | $ 103 M | ||
|
Amryt Pharma plc
AMYT
|
236 M | - | - | $ 621 M | ||
|
Kinnate Biopharma
KNTE
|
46.6 M | - | - | $ 123 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
162 M | - | - | $ 7.29 B | ||
|
NexImmune
NEXI
|
1.05 M | - | 70.13 % | $ 4.12 M | ||
|
Wave Life Sciences Ltd.
WVE
|
169 M | $ 3.23 | -0.16 % | $ 545 M | ||
|
Theravance Biopharma
TBPH
|
50.3 M | $ 17.03 | 0.03 % | $ 857 M | ||
|
Xenetic Biosciences
XBIO
|
1.7 M | $ 1.72 | 3.78 % | $ 2.93 M | ||
|
XBiotech
XBIT
|
30.5 M | $ 1.82 | -5.7 % | $ 55.5 M | ||
|
Xenon Pharmaceuticals
XENE
|
79.3 M | $ 35.76 | 1.19 % | $ 2.83 B | ||
|
Xeris Pharmaceuticals
XERS
|
160 M | $ 10.21 | 0.05 % | $ 1.64 B | ||
|
X4 Pharmaceuticals
XFOR
|
42.3 M | $ 3.26 | 0.46 % | $ 138 M | ||
|
IMV
IMV
|
8.34 M | - | - | $ 13.1 M | ||
|
22nd Century Group
XXII
|
184 K | $ 0.09 | -54.43 % | $ 16.6 K |